Business Overview: QT Imaging Holdings, Inc. (Nasdaq: QTI)

---

Executive Summary

QT Imaging Holdings, Inc. is a Novato, California-based medical device company that designs, manufactures, and commercializes whole-breast ultrasound tomography systems for breast imaging — a radiation-free, compression-free alternative and adjunct to traditional mammography. The company became a publicly traded entity in 2024 through a merger with the special-purpose acquisition company GigCapital5, Inc.

QT Imaging is still an early-commercialization company: FY2025 revenue of $18.9 million grew 288% year-over-year as the company shipped a record 40 scanners, but it remains unprofitable and dependent on a small number of exclusive regional distributors. Its significance lies less in current scale than in its position as one of a handful of FDA-cleared companies pursuing a genuinely different breast-imaging modality in a market still dominated by mammography and automated ultrasound incumbents.

---

1. Core Business Model & How They Work

QT Imaging sells capital medical equipment — breast imaging scanners — largely through exclusive regional distribution agreements rather than a direct global sales force, and is beginning to layer recurring service and software revenue on top of that hardware base.

[ R&D & FDA 510(k) Clearance ] ➡️ [ Manufacturing (Novato, CA + Canon CMSC contract) ] ➡️ [ Exclusive Regional Distributor Sale ] ➡️ [ Installed Base at Imaging Centers/Hospitals ] ➡️ [ Reimbursement Billing + Future Cloud/AI Software Revenue ]

Key Operational Drivers

1. Capital Equipment Sales via Exclusive Distributors: NXC Imaging (a Canon Medical Systems subsidiary) is the exclusive U.S. reseller; Al Naghi Medical Co. (UAE) and Gulf Medical Co. (Saudi Arabia) hold exclusive regional rights in the Gulf. Al Naghi alone has committed to minimum purchases of 43 scanners through 2028, representing more than $24 million of contracted future revenue — an unusual degree of forward revenue visibility for a company this size.
2. Dual-Source Manufacturing: Scanners are built both in-house in Novato and, since Q3 2025, in parallel through contract manufacturer CMSC (a Canon affiliate), with a liquidated-damages clause protecting QT Imaging if CMSC misses delivery windows.
3. Early-Stage Reimbursement Strategy: Because no dedicated CPT code yet exists, scans are billed case-by-case under an unlisted code; the company has applied for a New Technology APC and secured a Category III CPT code (X579T) effective January 1, 2027 — a meaningful but still-incomplete step toward predictable third-party reimbursement.
4. Planned Software/Cloud Layer: Partnerships with Intelerad and Olea Medical underpin a planned QTI Cloud Platform intended to add AI/machine-learning post-processing modules as a future recurring-revenue stream on top of the hardware installed base.

(QT Imaging operates as a single reporting segment — breast imaging systems — so no segment breakdown is presented.)

---

2. Product Portfolio

---

3. Competitive Landscape

Breast imaging is a crowded field dominated by mammography, but QT Imaging competes most directly against other non-mammography adjunct modalities:

• Automated Breast Ultrasound (ABUS) — the largest adjacent category (estimated $1B+ global market, growing ~13–16% annually): Siemens (Acuson S2000 ABVS), GE Healthcare (Invenia), Hitachi (Sofia), and Sono-Cine (manual AWBS). These are larger, better-capitalized incumbents with broader hospital distribution relationships.
• Ultrasound Tomography (direct competitor) — Delphinus Technologies' SoftVue system is QT Imaging's own predicate device and its closest technological peer; smaller research-stage systems exist in Greece and Germany but are not commercialized.
• Photoacoustic Imaging — Seno Medical's Imagio system, FDA-cleared as a handheld-ultrasound adjunct; no fully tomographic photoacoustic system is yet approved for clinical use, leaving QT Imaging's whole-breast approach relatively differentiated within this sub-category.
• Core modality (indirect competitor) — conventional mammography, MRI, and handheld ultrasound remain the standard of care and the benchmark QT Imaging must supplement rather than displace.

---

4. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Differentiated, FDA-Cleared Technology: A radiation-free, compression-free whole-breast imaging modality addresses two of patients' most commonly cited objections to mammography, giving the company a genuine (if niche) clinical differentiation.
• Contracted Distribution Revenue Visibility: The Al Naghi minimum-purchase commitment (43 scanners / $24M+ through 2028) is an unusually concrete forward revenue backstop for a company of this size.
• Early Reimbursement Progress: Securing a Category III CPT code ahead of full Category I/APC coverage is a genuine, if incremental, regulatory milestone that most pre-revenue medical device competitors never reach.

Strategic Risks & Vulnerabilities

1. Profitability and Cash Burn: FY2025 net loss was $21.1 million against $18.9 million of revenue, and the company used $9.0 million of operating cash during the year; continued execution of the aggressive FY2026 guidance (~$39 million, more than double FY2025) is required to narrow that gap.
2. Distributor Concentration: A large share of near-term revenue depends on a small number of exclusive distributors (NXC Imaging, Al Naghi, Gulf Medical); loss of or friction with any one relationship would materially affect results.
3. Incomplete Reimbursement Pathway: The Category III CPT code effective 2027 is not the same as guaranteed payer coverage — broader adoption still depends on payers choosing to reimburse a code that, by definition, lacks the established utilization data of a Category I code.
4. Single-Source Supply Risk: The company sources a critical ultrasound transducer subcomponent from one validated supplier under a purchase-order arrangement with no long-term written agreement, and relies on Canon affiliate CMSC for a portion of manufacturing capacity.
5. Financing Structure: The FY2025 results included a non-cash loss on a Lynrock Lake term loan and a rising warrant-liability fair value, both signs of a capital structure still being actively shaped as the company scales — a dynamic worth monitoring even though the company completed an $18.2 million private placement and a Nasdaq uplisting in October 2025.

---

5. Financial Overview

---

6. Summary Conclusion

QT Imaging Holdings' investment case rests on a genuinely differentiated, FDA-cleared breast imaging technology paired with unusually concrete contracted distribution commitments for a company of its size — a combination that produced 288% revenue growth in FY2025. But the company is still small, cash-burning, and dependent on a handful of exclusive distributor relationships and an incomplete reimbursement pathway, meaning its biggest forward risk is simple execution and financing risk: it must convert its distributor pipeline and FY2026 revenue guidance into durable, profitable scale before capital markets access becomes a constraint.